Duchesnay Pharmaceutical Group accelerates global growth with innovative technology supported by Investissement Québec's grand V initiative and the Government of Quebec
The consolidation of production capacity will enable the Group to meet the growing demand for its products around the world.
BLAINVILLE, QC, June 17, 2025 /CNW/ - Duchesnay Pharmaceutical Group (DPG), winner of the 2024 ADRIQ Life Sciences Innovation Award, is pleased to announce the installation of an additional state-of-the-art pharmaceutical tablet printer at its Blainville plant, which will increase its production capacity and support its international expansion. This acquisition was made possible thanks to support from Investissement Québec's grand V initiative and the Government of Quebec's ESSOR program.
With a production capacity of up to 150,000 tablets per hour, this new machine incorporates advanced technology that ensures the quality of the logo depicting a pregnant woman on the Group's flagship product which is exported to more than 40 countries. By consolidating its production capacity, the Group plans to support its international expansion by extending its global presence to 10 new markets over the next two years in order to meet the growing demand for its products.
"As it continues its global growth, the Group remains committed to excellence and innovation in supporting women's well-being around the world. The new machine will not only enable us to meet growing demand but also optimize our manufacturing processes in a sustainable manner. With the support of the grand V initiative, we are taking another step forward in our global expansion," said Mélanie Therrien, Vice President, Finance and Corporate Affairs, DPG.
"Supported by Investissement Québec's grand V initiative, Duchesnay Pharmaceutical Group has taken a step toward greater productivity by acquiring a new state-of-the-art printer. This new equipment will enable the company to significantly increase its production capacity and support its growth in the pharmaceutical sector," said Bicha Ngo, President and CEO of Investissement Québec.
With this strategic acquisition, DPG reaffirms its commitment to innovation and excellence and is fully aligned with the industrial transformation dynamic.
ABOUT DUCHESNAY PHARMACEUTICAL GROUP
Duchesnay Pharmaceutical Group (DPG), with its affiliated companies, is headquartered in Blainville, Quebec. The Group consists of six pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. The companies are Duchesnay (Canada) and Duchesnay USA, both dedicated to women's health; Medunik Canada and Medunik USA, which provide treatments for rare and debilitating diseases; and Analog Pharma Canada and Analog Pharma, specializing in orphan generic medications. From its state-of-the-art manufacturing plant, DPG exports its innovative treatments to more than 50 countries.
DPG is one of the eight companies across the country chosen to participate in the Government of Canada's Global Hypergrowth Project. This appointment offers exclusive and personalized support for at least two years, in order to accelerate its growth to become an anchor firm in the Canadian economy.
DPG is the winner of the 2024 Life Sciences Innovation Award by ADRIQ, the Association for the Development of Research and Innovation of Quebec, which recognizes DPG's healthy workplace culture and commitment to pharmaceutical innovation, while DPG president Éric Gervais is the recipient of the 2024 Bernard-Landry Award by ADRIQ which acknowledges his impactful leadership on Quebec's research and innovation ecosystem.
DPG, through its proprietary research and development, and through exclusive partnerships, offers innovative treatments for a variety of medical conditions in women's health, urology, oncology and for rare diseases, plus lower-cost generic medications. DPG recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and to giving back to the community through the support of various charitable organizations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
5 days ago
- Cision Canada
Duchesnay Pharmaceutical Group accelerates global growth with innovative technology supported by Investissement Québec's grand V initiative and the Government of Quebec
The consolidation of production capacity will enable the Group to meet the growing demand for its products around the world. BLAINVILLE, QC, June 17, 2025 /CNW/ - Duchesnay Pharmaceutical Group (DPG), winner of the 2024 ADRIQ Life Sciences Innovation Award, is pleased to announce the installation of an additional state-of-the-art pharmaceutical tablet printer at its Blainville plant, which will increase its production capacity and support its international expansion. This acquisition was made possible thanks to support from Investissement Québec's grand V initiative and the Government of Quebec's ESSOR program. With a production capacity of up to 150,000 tablets per hour, this new machine incorporates advanced technology that ensures the quality of the logo depicting a pregnant woman on the Group's flagship product which is exported to more than 40 countries. By consolidating its production capacity, the Group plans to support its international expansion by extending its global presence to 10 new markets over the next two years in order to meet the growing demand for its products. "As it continues its global growth, the Group remains committed to excellence and innovation in supporting women's well-being around the world. The new machine will not only enable us to meet growing demand but also optimize our manufacturing processes in a sustainable manner. With the support of the grand V initiative, we are taking another step forward in our global expansion," said Mélanie Therrien, Vice President, Finance and Corporate Affairs, DPG. "Supported by Investissement Québec's grand V initiative, Duchesnay Pharmaceutical Group has taken a step toward greater productivity by acquiring a new state-of-the-art printer. This new equipment will enable the company to significantly increase its production capacity and support its growth in the pharmaceutical sector," said Bicha Ngo, President and CEO of Investissement Québec. With this strategic acquisition, DPG reaffirms its commitment to innovation and excellence and is fully aligned with the industrial transformation dynamic. ABOUT DUCHESNAY PHARMACEUTICAL GROUP Duchesnay Pharmaceutical Group (DPG), with its affiliated companies, is headquartered in Blainville, Quebec. The Group consists of six pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. The companies are Duchesnay (Canada) and Duchesnay USA, both dedicated to women's health; Medunik Canada and Medunik USA, which provide treatments for rare and debilitating diseases; and Analog Pharma Canada and Analog Pharma, specializing in orphan generic medications. From its state-of-the-art manufacturing plant, DPG exports its innovative treatments to more than 50 countries. DPG is one of the eight companies across the country chosen to participate in the Government of Canada's Global Hypergrowth Project. This appointment offers exclusive and personalized support for at least two years, in order to accelerate its growth to become an anchor firm in the Canadian economy. DPG is the winner of the 2024 Life Sciences Innovation Award by ADRIQ, the Association for the Development of Research and Innovation of Quebec, which recognizes DPG's healthy workplace culture and commitment to pharmaceutical innovation, while DPG president Éric Gervais is the recipient of the 2024 Bernard-Landry Award by ADRIQ which acknowledges his impactful leadership on Quebec's research and innovation ecosystem. DPG, through its proprietary research and development, and through exclusive partnerships, offers innovative treatments for a variety of medical conditions in women's health, urology, oncology and for rare diseases, plus lower-cost generic medications. DPG recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and to giving back to the community through the support of various charitable organizations.
Globe and Mail
09-06-2025
- Globe and Mail
Inspired Announces Private Placement of £270 Million Senior Secured Notes and New £17.8 Million Credit Facility
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Inspired Entertainment, Inc. ('Inspired' or the 'Company') (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services, today announced the completion of a private placement by its subsidiary of £270.0 million aggregate principal amount of senior secured notes due 2030 (the '2030 Senior Secured Notes'). In connection with the placement, certain of its subsidiaries also entered into a new £17.8 million revolving credit facility (the 'Revolving Credit Facility'), which replaces its existing, and now terminated, revolving credit facility. The 2030 Senior Secured Notes will bear interest at a floating rate equal to SONIA plus a margin ranging from 550 to 600 basis points, based on the senior secured net leverage ratio of the Company's subsidiaries that form part of the 'Group' for the purposes of the 2030 Senior Secured Notes (the 'Group'). The 2030 Senior Secured Notes will mature on June 9, 2030. The new Revolving Credit Facility will mature on December 9, 2029, and will bear interest at a floating rate based on SONIA for sterling-denominated borrowings, plus a margin of 325 to 375 basis points, also based on the Group's senior secured net leverage ratio. Inspired intends to use the proceeds from the offering of the 2030 Senior Secured Notes to (i) redeem its existing £235 million senior secured notes due June 1, 2026 and repay the £15 million loans outstanding under its existing £20 million revolving credit facility (and any accrued interest and/or fees thereon, in each case), (ii) to pay fees, commissions and expenses related to the refinancing, and (iii) for general corporate purposes. The 2030 Senior Secured Notes were purchased by Barclays Bank plc, HG Vora Special Opportunities Master Fund, Ltd., BSE Investments, Ltd. and HG Vora Opportunistic Capital Master Fund III A LP and the Revolving Credit Facility was provided by Barclays Bank plc. Stifel served as financial advisor and exclusive debt financing agent to the Company and Davis Polk acted as legal advisor to the Company. The securities referenced herein have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. About Inspired Entertainment, Inc. Inspired offers an expanding portfolio of content, technology, hardware and services for regulated gaming, betting, lottery, social and leisure operators across retail and mobile channels around the world. The Company's gaming, virtual sports, interactive and leisure products appeal to a wide variety of players, creating new opportunities for operators to grow their revenue. The Company operates in approximately 35 jurisdictions worldwide, supplying gaming systems with associated terminals and content for approximately 50,000 gaming machines located in betting shops, pubs, gaming halls and other route operations; virtual sports products through more than 32,000 retail venues and various online websites; interactive games for 170+ websites; and a variety of amusement entertainment solutions with a total installed base of more than 16,000 terminals. Additional information can be found at Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our ability to bring certain of our products to customers in the various markets in which we operate and execute on our strategic plan, statements regarding expectations with respect to potential new customers and statements regarding our anticipated financial performance. Forward-looking statements may be identified by the use of words such as 'anticipate,' 'believe,' 'continue,' 'expect,' 'estimate,' 'plan,' 'will,' 'would' and 'project' and other similar expressions that indicate future events or trends or are not statements of historical matters. These statements are based on Inspired management's current expectations and beliefs, as well as a number of assumptions concerning future events. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of Inspired's control and all of which could cause actual results to differ materially from the results discussed in the forward-looking statements. Accordingly, forward-looking statements should not be relied upon as representing Inspired's views as of any subsequent date. You are advised to review carefully the 'Risk Factors' section of Inspired's annual report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent quarterly reports on Form 10-Q, which are available, free of charge, on the U.S. Securities and Exchange Commission's website at Inspired does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as required by law. For Press and Sales
Cision Canada
22-05-2025
- Cision Canada
EdgeCap-backed Comac Medical Group Expands with Acquisition of ILIFE Consulting, a French Early-phase Specialty CRO
Strategic acquisition marks significant step to establish pan-European footprint and deepens expertise in oncology and early-phase biotech clinical trials. LONDON, May 22, 2025 /CNW/ -- Comac Medical Group ("Group"), based in the UK and backed by EdgeCap Partners, announced today the acquisition of ILIFE Consulting ("ILIFE"), a specialized Contract Research Organization (CRO) headquartered in Paris, France, renowned for its expertise in oncology, rare diseases, and complex biotech clinical trials. The transaction represents a significant milestone for the Group on its journey to becoming the leading pan-European full-service CRO partner for small and medium-sized biopharma companies, and complements recent expansions into the United States, Germany, and the United Kingdom. Founded in 2013 by Marina Iché, ILIFE has built a distinguished reputation for delivering high-value strategic consulting alongside clinical trial execution for biotech sponsors. ILIFE's addition to the Group will leverage complementary expertise and reach, thus creating new opportunities for clients, who will benefit from a complete service offering, including enhanced capabilities in biostatistics, data management, pharmacovigilance, bioanalytical services, and Comac Medical's state-of-the-art Early Phase Clinical Research Unit. ILIFE's founder and CEO, Marina Iché, will continue in her leadership role and become a significant shareholder in the Group to support strategic growth initiatives and to maintain continuity of ILIFE's values and services that have driven its success positioning it as a trusted partner in the biotech ecosystem. Marina Iché, Founder and CEO of ILIFE Consulting, stated: "Partnering with EdgeCap and Comac Medical Group marks an exciting new chapter for ILIFE. We share a deep commitment to quality, innovation, client-centric and agile service delivery. We mobilize our resources and energy to ensure successful partnerships with our clients. We listen and capitalize on our expertise to identify and bring the best solutions to support our clients in achieving their goals productively and efficiently. Joining forces allows us to leverage additional resources, broaden our service portfolio, and better serve our clients across Europe and beyond. We rely on the competence and integrity of our team whose dedication and energy drive us to work swiftly towards obtaining actionable results. I remain fully committed to ensuring continuity in ILIFE's services while pursuing our mission to bring meaningful innovation to patients." Chris Smyth, Incoming CEO of Comac Medical Group, said: "ILIFE Consulting's expertise and established presence in the French biotech ecosystem significantly strengthen our capabilities as part of the Group. I look forward to working closely with Marina and the ILIFE team as we collaborate to create meaningful value for our stakeholders and deliver excellence across our expanded geographic and therapeutic landscape." Today's announcement closely follows the Group's recent leadership appointments and international expansion initiatives, including new executive appointments – Dr. Chris Smyth as incoming CEO (effective 1 st September 2025), Christian Buhlmann as Chief Commercial Officer, and Peter Windisch as Chief Operations Officer – and Neil Ferguson as Chairman of the Board. About ILIFE Consulting ILIFE Consulting is a Paris-based CRO specialized in early-phase oncology and biotech development. Since 2013, ILIFE has partnered with emerging biotech companies to deliver tailored strategic and operational support – from protocol design to full clinical trial execution, including first-in-human and multi-country studies. With deep expertise in oncology, rare diseases, novel therapeutic modalities, and complex regulatory environments, ILIFE accelerates timelines, optimizes data quality, and helps its clients make confident, value-driven decisions. Trusted by over 20 biotech sponsors across Europe, ILIFE's senior team of scientific and clinical leaders is committed to delivering high-impact studies that bring innovation closer to patients. About Comac Medical Group Based in London, United Kingdom, Comac Medical Group is one of the leading pan-European, full-service CRO platforms striving to be the partner of choice for small and medium-sized biopharma clients globally. The Group is present in more than 30 countries across Western Europe and Central and Eastern Europe, providing a comprehensive range of early to late-phase drug development services across a variety of therapeutic areas including oncology, rare diseases, dermatology, gastroenterology, and respiratory diseases. Comac Medical's FDA and EMA-inspected Clinical Research Unit (CRU) for Phase I, bioavailability and bioequivalence studies has 20 years of experience in early-phase clinical research. Based in Sofia, the facility is the largest in the region and comprises 42 beds, an on-site pharmacy as well as a clinical and bioanalytical laboratory. EdgeCap is a London- and Tallinn-based mid-market private equity and growth capital firm targeting investments into high-quality companies in Europe. We partner with ambitious founders and management teams to develop strong local businesses into pan-European and global champions. EdgeCap was founded in 2021 by Kristjan Piilmann and Chris Backes, who have 20+ years of combined private equity and investment banking experience at bulge bracket firms including PSG Equity LLP, Morgan Stanley, Citi and Goldman Sachs.
